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A Metastasis or a Second Independent
Cancer? Evaluating the Clonal Origin of
Tumors Using Array-CGH Data
Irina Ostrovnaya, Adam Olshen, Venkatraman E. Seshan, Irene Orlow, D G.
Albertson, and Colin B. Begg
Abstract
When a cancer patient develops a new tumor it is necessary to determine if this is
a recurrence (metastasis) of the original cancer, or an entirely new occurrence of
the disease. This is accomplished by assessing the histo-pathology of the lesions,
and it is frequently relatively straightforward. However, there are many clinical
scenarios in which this pathological diagnosis is difficult. Since each tumor is
characterized by a genetic fingerprint of somatic mutations, a more definitive di-
agnosis is possible in principle in these difficult clinical scenarios by comparing
the fingerprints. In this article we develop and evaluate a statistical strategy for
this comparison when the data are derived from array comparative genomic hy-
bridization, a technique designed to identify all of the somatic allelic gains and
losses across the genome. Our method involves several stages. First a segmen-
tation algorithm is used to estimate the regions of allelic gain and loss. Then the
broad correlation in these patterns between the two tumors is assessed, leading
to an initial likelihood ratio for the two diagnoses. This is then further refined
by comparing in detail each plausibly clonal mutation within individual chromo-
some arms, and the results are aggregated to determine a final likelihood ratio.
The method is employed to diagnose patients from several clinical scenarios, and
the results show that in many cases a strong clonal signal emerges, occasionally
contradicting the clinical diagnosis. The “quality” of the arrays can be summa-
rized by a parameter that characterizes the clarity with which allelic changes are
detected. Sensitivity analyses show that most of the diagnoses are robust when
the data are of high quality.
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Abstract 
 
When a cancer patient develops a new tumor it is necessary to determine if this is a 
recurrence (metastasis) of the original cancer, or an entirely new occurrence of the 
disease. This is accomplished by assessing the histo-pathology of the lesions, and it is 
frequently relatively straightforward. However, there are many clinical scenarios in which 
this pathological diagnosis is difficult. Since each tumor is characterized by a genetic 
fingerprint of somatic mutations, a more definitive diagnosis is possible in principle in 
these difficult clinical scenarios by comparing the fingerprints. In this article we develop 
and evaluate a statistical strategy for this comparison when the data are derived from 
array comparative genomic hybridization, a technique designed to identify all of the 
somatic allelic gains and losses across the genome. Our method involves several 
stages. First a segmentation algorithm is used to estimate the regions of allelic gain and 
loss. Then the broad correlation in these patterns between the two tumors is assessed, 
leading to an initial likelihood ratio for the two diagnoses. This is then further refined by 
comparing in detail each plausibly clonal mutation within individual chromosome arms, 
and the results are aggregated to determine a final likelihood ratio. The method is 
employed to diagnose patients from several clinical scenarios, and the results show that 
in many cases a strong clonal signal emerges, occasionally contradicting the clinical 
diagnosis. The “quality” of the arrays can be summarized by a parameter that 
characterizes the clarity with which allelic changes are detected. Sensitivity analyses 
show that most of the diagnoses are robust when the data are of high quality. 
 
KEY WORDS: Statistical diagnosis; Likelihood ratio; Array CGH; Second primary 
cancer; Cancer metastasis.
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1. Introduction 
 
The defining feature of cancer is metastasis, the ability of tumors to colonize distant sites 
of the body.  Independent (second primary) cancers also occur frequently.  
Distinguishing a second primary from a metastasis is often of great clinical relevance, as 
it can affect the appropriateness of local (surgical) versus systemic (medical) treatment.  
Historically pathologists have distinguished these on the basis of gross and microscopic 
pathologic criteria.  However, in recent years cancer investigators have begun to explore 
new methods to accomplish this by comparing the molecular profiles of the two tumors.  
These studies involve the side-by-side comparison of pairs of tumors (from the same 
patient) on the basis of patterns of somatic mutations, such as allelic gains or losses, 
micro-satellite instability, or point mutations in genes that frequently experience somatic 
mutations in tumors.  In this article we explore how to construct a formal statistical 
comparison of the mutational patterns in the setting in which the two tumors have been 
evaluated using genome-wide array comparative genetic hybridization (ACGH), a 
molecular genetic technique designed to identify allelic gains and losses across the 
entire genome of a tumor.  
 
These studies have potentially important clinical implications. For example, a patient 
treated effectively for a localized primary head and neck cancer may at a later date 
present with a solitary lung nodule. If the nodule is a localized second primary lung 
cancer it can be treated effectively by surgery, though lung surgery is risky and very 
invasive. On the other hand, if the tumor is a metastasis from the head/neck primary, the 
prognosis of the patient is necessarily poor, as the cancer will almost certainly have also 
metastasized to other parts of the body (even though these other metastases may not 
yet be detectable). In this case invasive surgery would impose needless risks and 
morbidity on a patient who will have relatively little time left to live. Yet if the two tumors 
have the same cell type the pathologist has essentially no direct evidence on which to 
base the diagnosis. 
 
In making this differential diagnosis our fundamental purpose is to determine whether or 
not the tumors share a clonal origin. That is, one wishes to determine if both tumors are 
derived from a single “clonal” cell that experienced the pivotal mutations that led to tumor 
development. Many studies exploring the use of molecular profiling in this context have 
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been conducted in recent years. For example, investigators studying lung cancer have 
used microsatellite markers to distinguish patterns of microsatellite instability (Huang 
2001, Dacic 2005, Geurts 2005, Leong 1998, Shin 2001) and several investigators have 
also used mutational analysis of the important cancer genes p53 and/or K-ras 
(Hiroshima 1998, Holst 1998, Lau 1997, Shimizu 2000, Shin 2001, Murase 2003, 
Matsuzoe 1999, Sozzi 1995, van Rens 2002). Similar studies have been conducted to 
distinguish contralateral breast cancers from metastases, and in other cancer sites 
(Imyanitov 2002, Regitnig 2004, Kollias 2000, Janschek 2001, Tse 2003, Schlechter  
2004, Stenmark-Askmalm 2001, Chunder 2004). By studying the mutational pattern, one 
can establish a genetic fingerprint of the tumor. When the mutational profiles of two 
apparently independent primary tumors from the same patient are compared, it is 
possible in principle to see whether these genetic fingerprints are sufficiently similar that 
we can determine with confidence that they share a clonal origin, i.e. the second primary 
is really a metastasis from the first primary.  
 
The comparison of mutational profiles of tumors to determine clonality is a challenging 
statistical problem, and a number of authors have proposed techniques for this purpose. 
In earlier work we examined two new statistical tests, based on the setting in which the 
mutational events at candidate genetic loci are assessed for correlation, with a view to 
determining if the correlation exceeds the level that is plausible on the basis of chance 
(Begg et al. 2007, Ostrovnaya et al. 2008). These tests have been shown to be 
reasonably powerful provided that information is available from a considerable number 
of candidate genetic loci that experience mutational events with reasonably high 
frequency in the cancer under study, and that the “signal” is relatively strong, i.e. the 
preponderance of the observed somatic mutations occur in the clonal phase of 
development. Other authors have approached this problem in different ways. For 
example Sieben et al. (2003) and Brinkmann et al. (2004) both construct likelihood ratios 
to distinguish the evidence favoring the two hypotheses, though the construction is 
somewhat different in each case. Another approach was advocated in earlier work by 
Kuukasjarvi et al. (1997), who proposed a measure of clonal relatedness based on the 
frequency of occurrence of concordant mutations in the tumors, and this measure has 
been used by other authors such as Jiang et al. (2005) and Goldstein et al. (2005a,b).  
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The preceding methods are all based on the setting in which we observe mutations in a 
pre-specified set of candidate markers in each tumor, and we evaluate the collective 
concordance of these mutational profiles. However, there are a limited number of 
genetic loci at which mutations are known to occur frequently in tumors, and these tend 
to differ between cancer sites. As a result, sometimes very few mutations are observed 
in a specific patient, even when a relatively comprehensive set of loci have been 
examined, and so there can be limited statistical power to distinguish the two diagnoses 
reliably (Orlow et al. 2008). Since the common somatic mutations in tumors are 
frequently losses or gains of segments of DNA, the issue of clonality can be studied for 
the entire genome using array technology, specifically array comparative genomic 
hybridization (ACGH) (Pinkel et al. 1998). By scanning the entire genome for copy 
number changes this technology has the potential to provide a comprehensive 
comparison of the two mutational profiles, and to provide insights beyond those available 
from studies using a pre-defined set of candidate markers. In particular, ACGH can 
pinpoint the places in the genome where these gains and losses begin and end, offering 
the potential for identifying the exact matches that are the hallmark of clonal mutations.   
 
Statistical methods for comparing ACGH data in this context have typically employed 
strategies that simply count mutational events, as in the methods described above for 
studies based on markers at candidate genetic loci. For example, investigators have 
used data from the arrays to define the presence or absence of, say, loss of 
heterozygosity (LOH) at the level of the chromosome arm (Jiang et al. 2005) or 
chromosome band (Teixeira et al. 2004) in order to define the unit of analysis for 
statistical tests or clustering algorithms. Many investigators have evaluated the similarity 
between profiles only visually and through listing the chromosomes arms or bands that 
have similar and different alterations, for example Nishizaki (1997), Weiss (2003), Wa et 
al. (2005), Knosel (2005), Ruiz (2007) , Park (2007), Nestler (2007), Haller (2007) and 
Agaimy (2007). More specific approaches have been used by Waldman et al. (2000) 
who employed three distinct strategies for classifying pairs of tumors as clonal or 
independent. First, these investigators used hierarchical clustering of the marker values 
on the array, designating tumors as clonal if they cluster together in a pair. Hierarchical 
clustering has also been used by Ghazani et al (2007), Teixeira et al. (2004) and 
Agelopoulos (2003). Another strategy considered by Waldman et al. is to simply report 
the percentage of chromosome arms with concordant gains or losses. Finally, this group 
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has used a similarity score that characterizes the broad correlation of gains and losses 
across chromosome arms. The similarity score is then benchmarked against the 
distribution of this measure when tumors from different patients are compared. Some of 
these strategies were further used in Hwang (2004) and Nyante (2004), published by the 
same group, and Torres (2007). 
 
None of these methods have taken advantage of the distinctive evidence available from 
ACGH data when compared with studies involving candidate genetic loci, namely the 
granularity of the information regarding the allelic gains and losses. In principle, this 
feature of the data provides the ability to pinpoint the start and stop regions of the allelic 
changes, with a view to determining an exact match between the mutations on the two 
tumors. An exception is the recent article by Bollet et al. (2008) where a modified version 
of the similarity score proposed by Waldman et al. (2000) was used to reflect the relative 
frequency of exact matches of estimated end points of detected allelic changes. In our 
experience the noise level in the arrays is usually too great to identify the exact 
endpoints of the allelic changes with confidence, and so matching algorithms need to 
address directly the statistical variation in the estimation of where allelic changes have 
occurred, and the positioning of the endpoints of the gain or loss. Furthermore, a 
comprehensive approach for making the diagnosis of the second tumor as clonal versus 
independent (of the first tumor) needs to take into account the broad correlation of the 
observed allelic gains and losses on the two tumors, as well as interrogating specific 
matching gains and losses to determine the probabilities that these matches represent 
clonal somatic events. In this article we outline a comprehensive statistical diagnostic 
strategy constructed along these lines, explore its performance on several available 
datasets, and describe a research agenda that will be needed to validate its statistical 
properties.  
 
 
2. Examples 
 
We utilize data from various sources to illustrate the challenges faced. These include 
two unpublished studies in which we are involved as co-investigators, and two studies 
from the literature for which the data are publicly available. 
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We introduce the problem in the context of an example in which the evidence favoring 
the clonal origin of the pair of tumors is quite strong. This involves two squamous cell 
tumors from a patient with cancer of the mouth. These were suspected of being related 
tumors by the pathologist, and indeed the molecular profiles support this diagnosis. The 
two tumors have been analyzed using a BAC array (Pinkel et al. 1998; Snijders et al. 
2001), and the results are displayed in Figure 1. Each dot on the graph is a marker value 
that represents the allelic copy number at a specific genetic locus (there are 
approximately 2400 such markers on a BAC array). The markers are displayed 
sequentially across the 22 chromosomes, with the two tumors aligned vertically. 
Chromosomes X and Y are excluded. The horizontal black lines represent the normal 
copy number (i.e. the expected 2 copies). If the markers in a region are significantly 
higher than the black line then we conclude that there has been an allelic gain, and 
these are represented by red lines. Allelic losses (below the line) are represented by 
blue lines.  The locations of gains and losses are determined by a statistical 
“segmentation” algorithm. Many statistical techniques for ACGH segmentation are 
available. We have used the circular binary segmentation (CBS) algorithm (Olshen et al. 
2004), a method that has been shown to have good statistical properties (see Lai et al. 
2005; Willenbrook and Fridyland 2005). For Figure 1, and throughout this manuscript, 
we have used a one-step CBS algorithm that picks the most prominent allelic change 
within a chromosome arm but does not search for more complex patterns of gains 
and/or losses (see later discussion). We used a significance level of 0.01, and further 
considered a significant segment to be a true allelic change only if the mean marker 
value in the segmented band exceeded a distance of 1.25 median absolute deviations 
(1.25 MAD criterion) from the normal copy number benchmark. This further criterion is 
intended to eliminate experimental artifacts such as batch effects. Note that the 
thresholds for gain or loss are different for every array and depend on the noise level. 
 
The plots in Figure 1 show a broad correlation between the patterns of allelic changes. 
For example there appears to be a loss of the entire chromosome arm on 3p on both 
tumors. Other concordant whole arm changes are observed for 8q(gain), 
16q(gain),19p(gain) and 20p(gain). In general, the losses and gains appear to be fairly 
strongly correlated. That is there seem to be more concordances than we might expect 
by chance. However, the real strength of the evidence favoring the clonal origin of these 
tumors lies in the precision of the matching of allelic changes that occur within 
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chromosome arms. For example there is a common loss on 10q, and a magnified 
display of the results for this chromosome arm is provided in Figure 2. Here we see 
strong evidence of a region of loss in the middle of the arm that looks similar in both 
tumors. If this allelic loss is indeed “clonal”, then the true change must begin and end at 
exactly the same genetic locations. However, the noise in the marker values, and the 
resulting uncertainty surrounding the estimation of the region of loss, can lead to 
statistical error in the estimated regions of loss. For 10q the regions of loss are closely 
but not exactly matched. Nonetheless, this does appear, visually, to be a plausible clonal 
event. Our challenge in this article is to assess the strength of evidence for and against 
the hypothesis that this event is indeed clonal. We then need to aggregate this evidence 
with the evidence from all of the other chromosome arms in order to obtain a diagnosis 
for the two tumors. We note that this patient is from a study of 21 head and neck tumors 
from 9 patients conducted at the University of California, San Francisco by one of us 
(DGA), and we will present an analysis of this patient and a summary of the analyses for 
all tumor combinations later in Section 5. 
 
Typically, the evidence for or against clonality is much less clear-cut than for this patient. 
Our second example involves two skin melanomas that have been diagnosed in the 
same patient. These melanomas were classified as independent primaries by the 
pathologist, and they occurred 2.4 years apart in distinct anatomic locations, one on an 
arm and the other on a leg. This time the arrays are from the 244K Agilent platform, an 
array with far more marker values than the BAC arrays featured in the first example. 
However, the data for this patient are quite noisy, and so we elected to perform our 
analyses using new marker values that represent averages of 49 adjacent markers. This 
averaging was accomplished to reduce the degree of scatter. It also leads to a total 
number of markers that is of the same order of magnitude as for the BAC arrays. This 
patient’s data are plotted in Figure 3. For these two tumors there are some notable 
similarities. Indeed the patterns in the higher numbered chromosomes are visually 
similar, and there is a moderately strong overall correlation across the genome, 
suggesting that the clinico-pathological diagnosis that the two melanomas are 
independent may be wrong. However, comparison of concordant within-arm allelic 
changes reveals only one change that strongly favors a clonal origin (on 2p) while most 
of the other observed changes appear to represent independent somatic events. This 
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patient is from a study of clonality in 19 patients with double primary melanomas (Orlow 
et al. 2008). 
 
We also analyze in detail publically-available datasets from two published studies. In the 
first study (Bollet et al. 2008) the investigators have examined pairs of breast cancers 
that occurred separately within the same (ipsilateral) breast in 22 patients. Some of 
these tumor pairs are suspected to be independently occurring breast cancers on the 
basis of clinico-pathologic information, while in other cases the second tumors are 
suspected to be metastases. The ACGH data were obtained from the Affymetrix 
Genechips Human Mapping 50K Array and are available through ACTuDB (Hupe et al. 
2007). In order to magnify the signal and diminish the array artefacts we are using these 
data averaged over 15 adjacent markers in our analysis. Again this leads to a total 
number of markers of a similar order of magnitude as the other datasets. In a second 
study, also involving breast cancer, Hwang et al. (2004) have studied the tumors from 
women with an invasive lobular carcinoma (ILC) who had previously been diagnosed 
with lobular carcinoma in situ (LCIS). Here the investigators were interested in the 
scientific issue of whether LCIS is a precursor lesion for invasive breast cancer. This 
dataset involves 24 pairs of tumors, and the tumors were analyzed using BAC arrays 
with a total of approximately 2400 markers.  
 
 
3. Conceptual Model 
 
Our analytic goal is conceptually straightforward. We wish to determine whether the two 
tumors are biologically independent, or whether the tumors are clonally related, i.e. both 
originating from the same “clonal” cell in which the acquired pivotal mutations occurred 
that provoked the cell to proliferate uncontrollably, leading ultimately to cancer. Thus, in 
our hypothesis of independent origin of the tumors, the sets of somatic mutations on 
each tumor must have occurred independently of each other. Under the clonal 
hypothesis the two tumors must possess one or more mutations that are identical. The 
existence of these clonal mutations ensures that a positive correlation in the mutational 
profiles would be expected, and so examination of the strength of this correlation is a 
major aspect of our analysis. However, we note that correlation of the patterns of gains 
and losses is likely even in independent tumors. This is because allelic gains and losses 
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tend to be observed in tumors in genetic regions for which there is a selective 
advantage, such as in the neighborhood of oncogenes or tumor suppressor genes. 
Thus, even in the absence of clonal origin of the tumors, there will be a common 
tendency for gains and losses to occur on the same chromosome arms. Our methods 
adjust for this phenomenon using background data to estimate the probabilities of gains 
and losses for each chromosome arm for the cancer type under investigation. Also, in 
clonal tumors, we expect additional “independent” allelic changes in each cell colony to 
occur, thereby adding “noise” to the clonal signal. Statistical noise in the marker values 
can also be accentuated for various experimental reasons: the tumor sample may be 
contaminated with an unknown proportion of normal cells; the tumor itself may have 
developed considerable heterogeneity of cell clones with distinct somatic changes; there 
may be artefacts in the array technology; there may be copy number variants in the 
germ line that masquerade as clonal events.  
 
After examining the broad pattern of correlation across the genome, we examine more 
carefully the specific chromosome arms on which concordant mutations have been 
observed, i.e. a loss on both tumors or a gain on both tumors. We examine the exact 
locations of these allelic gains or losses to determine the plausibility that the two 
changes are actually clonal, i.e. they represent the same change that occurred in the 
original clonal cell. We have developed new methodology for accomplishing this 
comparison. Our overall strategy is based on the premise that these precise within-
chromosome comparisons provide the most compelling evidence for identifying clonal 
tumors. 
 
We approach the problem from a “theoretical” perspective. That is, we construct a 
sampling model that we conjecture to be a realistic representation of the way in which 
the marker data are generated under the two competing diagnoses (independent origin 
of the tumors versus clonal origin). This model is then used to obtain statistical results 
that characterize the relative strength of the evidence favoring each of these 
hypotheses. The results are expressed as likelihood ratio statistics. Ultimately, a more 
satisfying (and better calibrated) strategy may be to generate an optimal discrimination 
measure, and then characterize the distribution of the measure in training data 
consisting of tumor pairs “known” to be clonal and pairs known to be independent, all 
derived from the relevant clinical scenario under investigation, e.g. cancers of a specific 
http://biostats.bepress.com/mskccbiostat/paper15
 10
anatomic site and/or cell type. However, at present there are very few data of this nature 
available, and indeed one cannot be sure that diagnoses based on classical pathology 
are correct. That is, our problem is akin to the creation and evaluation of a diagnostic 
test when there is no “gold standard” reference test (Begg 1987).  Despite this problem 
our diagnostic setting is unusual in that we can construct plausible reference 
distributions for our diagnostic test statistics under the “independence” hypothesis. We 
can do this by pairing tumors from different patients. By definition, all such pairs of 
tumors must have occurred independently. We use this strategy to calibrate our results 
for each dataset.  
  
 
4. Detailed Analytic Model 
 
The initial step of the analysis is a segmentation analysis of each of the chromosome 
arms of the two tumors (see Figures 1 and 3). In our analyses we have used the CBS 
algorithm with the significance level and further constraint as defined in the previous 
section. This analysis allows us, for each chromosome arm of each tumor, to assign the 
arm as representing an allelic gain, a loss, or no change. Comparing the patterns from 
the two tumors, we identify arms in which gains occur in both tumors or losses occur in 
both tumors. We define the former as “concordant gains”, and the set of such arms is 
represented by gΨ . Likewise the set of arms with concordant losses is denoted lΨ .  
 
Correlation of Mutational Patterns 
 
The arrays we have been using contain sufficient data for 39 autosomal chromosome 
arms that are considered to be statistically independent units of the genome. Let 1=ggir  
if gains are observed on the ith chromosome arm on both tumors (0 otherwise), 1=llir if 
losses are observed on both tumors, 1=glir if there is a gain on one tumor and a loss on 
the other, 1=gnir if there is a gain on one tumor and no change on the other, 1ln =ir if 
there is a loss on one tumor and no change on the other, and 1=nnir  if there is no 
change on either tumor. In evaluating the correlation in these outcomes between the 
tumors we must recognize the fact that the probabilities of gains and losses will be 
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specific to each chromosome arm, in addition to being specific to the tumor type under 
investigation. For the ith chromosome arm let these probabilities be gip  for a gain, lip for 
a loss, and nip  for no change, with 1=++ niligi ppp . Our analytic strategy requires 
knowledge of these marginal probabilities, and there are growing data resources for this 
purpose. However, in our analyses we have calculated the empirical relative frequencies 
of gains and losses in each dataset using the cohort of pairs of tumors being analyzed, 
and have used these as estimates of ,*gip  ,
*
lip  and .
*
nip  We then obtained patient-
specific estimates of the marginal probabilities using 
∑++= ,39/)(log/]78/)2[(log)(log)(log ** gignglgggigi pitrrritpitpit and analogous 
formulas for lip and nip , where ∑=
i
ggigg rr , etc. We have used these rescaled 
probabilities to avoid the risk of creating extreme results merely because the overall 
mutation frequency is unusually low or high for the patient, since this overall frequency is 
in part determined by the “quality” of the array data (see Sections 5 and 6).  
 
For our problem of differential diagnosis we have chosen to evaluate the evidence 
distinguishing the two diagnoses ( IH , the independence hypothesis, and CH , the 
clonal hypothesis) using likelihood ratios. As our knowledge develops, it should be 
possible to refine the diagnostic strategy to accommodate the prior probabilities for each 
diagnosis, based on the long-term relative frequencies of the two diagnoses in the 
clinical scenario, adjusted also possibly using relevant clinical information, such as the 
concordance of cell type and other features that inform current pathologic diagnostic 
rules. 
 
We construct a likelihood as follows: 
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where },,,,,{ ln nniigniglilliggi rrrrrrr =  represents the pattern of gains and losses across all 
of the chromosome arms. The parameter c  represents, in clonal pairs of tumors, the 
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proportion of observed mutations that are expected to be clonal, and we assume that 
this proportion applies to both gains and losses equally.  By specifying a value for c  we 
can obtain the likelihood ratio for the clonal versus the independence diagnoses using 
)0|(/)|( =crPcrP .  
 
Comparisons of Specific Concordant Mutations 
 
We augment the broad evaluation of correlation across the genome with specific 
comparisons for chromosome arms on which a common overlapping loss or gain 
spanning only a part of a chromosome has been observed on both tumors. The goal is 
to assess the evidence for and against the clonal origin of each specific mutational 
change. Let ukx represent the measurement of the 
thu  marker of the thk  tumor on a 
specific chromosome arm which has concordant allelic changes on the two tumors, 
where ,,..,1 nu =  and ,2,1=k  and where n  represents the number of markers on the 
chromosome arm. Let the copy number change begin at marker ki  and end at marker 
kj  for the 
thk  tumor. That is, markers ki  through kj , inclusive, represent the markers of 
allelic gain (or loss). If the mutation under investigation is clonal then 21 ii =  and 21 jj = .   
 
The CBS algorithm is used to obtain estimates of the endpoints, denoted kiˆ  
and kjˆ . We define a “closeness” statistic ,t  representing the similarity of the length and 
positioning of the two changes: 
      .ˆˆˆˆ 2121 jjiit −+−=                                                    (2) 
Thus small values of t are indicative of a possible clonal mutation. Under IH  we assume 
that the allelic changes have arisen independently, and so the reference distribution for t 
under IH  should thus reflect the distribution of t when independent allelic gains or losses 
have been generated on each tumor. To generate an appropriate reference distribution 
we must recognize that while chromosomal breakpoints may occur randomly in cells, the 
alteration is more likely to be retained if it contains a gene or genes for which there is an 
advantage to having an abnormal number of copies, such as an oncogene or a tumor 
suppressor gene. To address this phenomenon we first generate a location for a 
hypothetical mutational hotspot, which we presume to be located where the observed 
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regions of allelic loss or gain on the two tumors overlap. We then randomly generate 
new (true) regions of allelic change for the two tumors, restricted to the set of changes 
that overlap the hotspot. We permute the data (as described below) and use the CBS 
algorithm on the permuted data for each tumor to estimate the start and stop points for 
the allelic changes. If concordant allelic changes are detected by CBS on both tumors 
then the data set is considered to be “admissible”, and the estimated endpoints are used 
to calculate the reference test statistic. Re-applying the same segmentation algorithm 
(CBS) to the data simulated in the reference distribution automatically adjusts the 
procedure for the segmentation error. This process is then repeated a large number of 
times to establish the reference distribution for t  under IH .  
 
Let the sample means of the segmented marker values be 
∑
=
+−=
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kkukk ijx
ˆ
)1ˆˆ/(μˆ for the mutated portion and 
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1
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−
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θ  for the normal copy number portion. These are 
used to obtain residuals for each of the marker values:- 
kukuk xr θˆ−=  for kiu ˆ<  or kju ˆ>  
kukx μˆ−= for kk jui ˆˆ ≤≤ . 
The reference distribution is constructed using the following steps. [An asterisk denotes 
terms representing the reference distribution.] 
(1) Generate the location of the mutational hotspot *h , where *h  is selected 
uniformly from the common interval, i.e. the interval between max )ˆ,ˆ( 21 ii and min 
).ˆ,ˆ( 21 jj If the intervals do not overlap, separate hotspots are generated for each 
tumor. [For simplicity we assume that the hotspot occurs at a marker value, and 
define U ),( ji  to represent uniform sampling of the markers between i  and ,j  
inclusive.]  
(2) Generate the “true” endpoints of the allelic changes in the reference sample: 
*
1i and 
*
2i sampled from U(1, 
*h ) and *1j and 
*
2j sampled from U(
*h ,n).  
(3) Obtain },{ *ukr a permuted set of the residuals },{ ukr  permuted separately for each 
tumor. 
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(4) Create the permuted marker values }{ *ukx  using 
** ˆ
ukuk rx += θ  if *kiu < or *kju >  
       *ˆ ukr+= μ  if ,** kk jui ≤≤  
 where 
.
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(5) Segment the new datasets to obtain the estimated endpoints of the regions of 
allelic change, denoted )ˆ,ˆ( *1
*
1 ji  and ).ˆ,ˆ(
*
2
*
2 ji  Include the results only if these 
changes are both determined to be significant by the CBS segmentation method. 
(6) Calculate the reference value for the test statistic using 
.ˆˆˆˆ *2
*
1
*
2
*
1
* jjiit −+−=  
(7) Repeat the process a large number of times to obtain the distribution of *t . 
 
A reference distribution for t  under the clonal hypothesis CH  can be generated in 
exactly the same manner, merely by changing step 2. Here we randomly generated the 
endpoints of the allelic change below and above the hotspot, *i  from U(1,h ), and 
*j from U( nh, ), and set **2
*
1 iii ==  and 
**
2
*
1 .jjj ==  Also, in step 2, if the intervals do 
not overlap, a single hotspot is generated between the two intervals. 
 
Smoothed estimates of these two reference distributions (densities), denoted )(tf I  and 
)(tfC , are then obtained using kernel density estimation, with a standard default R 
bandwidth selection and kernel (Sheather and Jones 1991). The ratio )(/)( tftf IC  is 
then used as the likelihood ratio to characterize the evidence for and against the 
hypothesis that the mutation under investigation is clonal.  
 
In an effort to assess the validity of this strategy from a purely statistical perspective we 
have evaluated its frequentist properties by performing simulations in which the 
reference distribution of t  is evaluated under a model in which the two mutations are 
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generated independently, and the noise in the marker values is generated by a normal 
distribution. Specifically, we determined the mean value for markers at normal copy 
number, denoted by θ , and the mean in the region of allelic change, denoted by ,μ with 
common variance .2σ  These were chosen to specify the signal strength, represented by 
,/σθμ −  and one of the means was set to 0 and the variance set to 1 without loss of 
generality. For each simulation we first selected a true mutational hotspot at markerh . 
This was randomly generated from the n markers for each data set. We then generated 
a data set as follows. First the “true” endpoints of the allelic changes were randomly 
generated, 1i and 2i as U(1, h ), and 1j and 2j as U( nh, ). Observed marker values were 
generated as normal random variables. That is, ukx  was generated as N( ),
2σθ for kiu <  
or kju >  and as N( ),
2σμ for kk jui <<  The CBS algorithm was used on these data to 
estimate the endpoints, denoted ,ˆ,ˆ,ˆ,ˆ 2211 jiji  and the test statistic t  was calculated using  
(2).  
 
Following the procedure outlined above, the tail area probability (p-value) was calculated 
as the relative number of times that tt ≤* based on 1000 replicates from the reference 
distribution. The entire process was then repeated 1000 times to determine the relative 
frequency matching the tail-area probabilities generated by the algorithm. The simulation 
standard error is about ± 0.02. The procedure was allowed as many attempts as 
necessary to complete the 1000 replicates required, and likewise it was allowed as many 
attempts as necessary to generate a significant, concordant data set. In configurations 
with a signal strength ranging from 0.5 standard deviation units to 3, and numbers of 
markers from 65 to 140 (the typical numbers of markers on a chromosome arm of the 
arrays used in some of our examples, after data averaging) the observed relative 
frequencies from the simulation ranged from 0.02 to 0.06 for tail-area probabilities less 
than 0.05 as determined by our permutation-based algorithm. This exercise gives us 
confidence that our permutation-based procedure produces tail-area probabilities that 
are approximately accurate when data are generated using normal errors in the marker 
values. 
 
Global Analysis and Patient Diagnosis 
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The final step in the analysis is the aggregation of the evidence obtained from the 
correlation of the broad mutational patterns and the similarity analyses of specific 
concordant mutations. This provides a final assessment of the strength of the evidence 
favoring IH  versus CH   for the two tumors. We create an augmented likelihood that 
combines the evidence from these two sources. To do this we need to recognize that 
even for clonal tumors not all observed mutations are expected to be clonal. However, 
since our likelihood only involves comparison of potentially clonal concordant mutations, 
we need a mixing parameter that represents, under the clonal hypothesis, the proportion 
of “concordant” mutations that are expected to be clonal (as opposed to the proportion of 
all observed mutations that are clonal, denoted by the parameter c ). Setting 
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the full likelihoods under the two hypotheses can be expressed as follows: 
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where )( iIi tf and )( iCi tf represent the reference distributions of the similarity statistic it  
for the comparison on the thi chromosome arm. 
 
Ultimately the differential diagnosis for the patient under investigation depends 
on the prior probabilities of these two diagnoses, reflecting the long-run relative 
frequencies with which pairs of tumors in the given clinical setting are clonal or 
independent, augmented if necessary with other relevant information extraneous to the 
mutational profiles. If the prior probability that the tumors are clonal is defined to beπ , 
and the corresponding posterior probability is Π , then the posterior odds is given by  
.
11 I
C
L
L
•
−
=
Π−
Π
π
π
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However, in the absence of meaningful prior information in our present state of 
knowledge, we focus on likelihood ratios throughout, effectively assuming that .5.0=π  
 
 
5. Data Analyses 
 
We analyze initially the illustrative cases that were described earlier in Section 2. Data 
from the first of these, involving two squamous cell tumors from a patient with cancer of 
the mouth are presented in Figures 1 and 2. The segmentation analysis reveals 8 allelic 
gains in tumor 1 and 7 allelic gains in tumor 2, with 4 of these occurring on the same arm 
(concordant gains). There are 8 losses on tumor 1 and 11 losses on tumor 2, and 7 of 
these are concordant losses. The resulting likelihood ratio statistic using (1) is 214 to 1 in 
favor of clonality versus independence. In other words, the degree of broad correlation in 
allelic gains and losses is quite strongly supportive of the clonal hypothesis. Of the 11 
chromosome arms with concordant changes, several involve a whole arm gain or loss in 
at least one of the tumors. Thus there are 6 arms remaining for which we can conduct 
the detailed comparison of the endpoints of the changes. One of these comparisons 
(10q) is plotted on Figure 2. The odds for this loss favor the clonal hypothesis by a factor 
of 3 to1. Of the 5 remaining comparisons three favor the clonal hypothesis: 8q, 79 to 1; 
11q, 120 to 1; 18p, 34 to 1. The remaining two comparisons appear to represent 
independent mutations: 5q, 6 to 1 in favor of independence; 13q, 5 to 1 in favor of 
independence. When these comparisons are augmented with the broad comparisons 
using (2), the odds for clonality are 5.5 X 106 to 1, overwhelmingly favoring the common 
clonal origin of these two tumors.  
 
Our second example from Section 2 comes from a study of 19 patients with double 
primary melanomas that were assembled to examine the possible relationship of second 
primary melanomas with their initial primaries. These samples were examined for LOH 
at a set of candidate markers, and the results seem to confirm generally that most if not 
all of the tumors are independent (Orlow et al. 2008). However, for two of the 19 
patients, the comparison of the LOH profiles was marginally statistically significant, and 
for one of these we had sufficient tumor tissue to obtain ACGH on both tumors (note that 
most primary cutaneous melanomas are too small for CGH analysis using current 
technology). This case is displayed in Figure 3. The likelihood ratio from the broad 
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correlation of the gains and losses favors independence with odds of 31 to 1. There are 
3 concordant mutations amenable to a comparison of the specific changes with the 
following results: 2p, 15 to 1 favoring of clonality;  17q, 5 to 1 favoring independence; 
22q, 1.3 to 1 favoring independence. Thus the aggregate likelihood ratio is 13 to 1 in 
favor of independence. 
 
These previous examples lead us to likelihood ratios that ideally represent the strengths 
of evidence favoring each of the hypotheses/diagnoses for the patient, IH  versus CH . 
For the first patient we arrived at odds for CH  of 5.5 x 106 to 1. But do these seemingly 
overwhelming odds really supply the certainty of the diagnosis of CH  that the numbers 
imply? All of the examples we present involve clinical scenarios where the “correct” 
diagnosis is uncertain. That is, clinical and pathological data do not provide us with a 
“gold standard” reference diagnosis, and indeed a goal of research into the use of 
molecular techniques such as ACGH in this setting is to provide a more accurate 
standard. However, when we have at our disposal a more complete dataset of patients 
from the clinical scenario under investigation, we can create a plausible reference 
distribution for our diagnostic statistics under IH  by comparing pairs of tumors from 
different patients, tumors which necessarily arose independently. In the following more 
comprehensive analyses we use this strategy to add further insights into the properties 
of our method. 
 
First we examine the 22 patients from the study by Bollet et al. (2008). Clinical details 
are provided in Table 1, along with the diagnostic classifications based on our analyses. 
The goal for each patient is to determine if a second ipsilateral breast cancer is a new 
primary or a recurrence of the initial primary cancer. Clinical diagnoses were determined 
based on the congruence of the histology and location of the tumors. Second tumors 
were classified as recurrences (i.e. clonal, C) if they had the same histologic subtype, a 
similar or increased growth rate, a similar or loss of dependence on either estradiol or 
progesterone, and a similar or increased differentiation compared with the initial primary 
(see Bollet et al. 2008). On this basis, 9 of the 22 patients were classified as 
independent primaries (I), and the remaining 13 were classified as clonal (C). The final 3 
columns of Table 1 show the broad likelihood ratio calculations using (1), the likelihood 
ratio augmented with results from specific within-chromosome comparisons using (3), 
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and the diagnoses based on the latter statistics. For this dataset we classified cases as 
independent if ln(LR2) < -0.5, equivocal if -0.5 < ln(LR2) < 6, and clonal if ln(LR2) > 6, for 
reasons further described below. Our classifications are mostly in agreement with the 
clinical classifications, with the notable exception of case #22. For this case, considered 
clinically to represent two independent tumors, the broad correlation (LR1) modestly 
favors the clonal hypothesis but there are individual mutations that point strongly to 
clonality on 8p (80 to 1) and 11q (36 to 1), leading to a final likelihood ratio in favor of 
clonality of 3.6 x 103 to 1. These individual mutations are plotted on the top two panels of 
Figure 4. Interestingly, this case also highlights some of the practical difficulties we face 
in accounting for the evidence in a fully algorithmic way. Although our method identifies 
most potentially clonal mutations, it will occasionally miss some possible candidates due 
to arbitrary features of the selection algorithm. For example, we only compare mutations 
that are both designated as either gains or losses. In the lower two panels of Figure 4 we 
see highly plausible clonal mutations that were missed. For 6p, the short segment in the 
first tumor (top panel) is considered a loss, while for the second tumor the long segment 
is considered a gain. This is because we make the classification of gain versus loss on 
the basis of the distance from the normal copy number, itself estimated from the average 
of all the markers in the array. Yet, this clearly looks like a highly plausible clonal event. 
A similar pattern emerges in 13q. Thus the evidence for clonality in this patient may be 
substantially stronger than is represented by the formal analysis. 
 
This patient represents an example of a case in which the molecular evidence seems to 
clearly contradict the diagnosis based on standard clinical criteria. However, the data are 
not always so clear-cut, and it is also much harder to be convinced that two tumors are 
independent, since independence is characterized (visually) merely by the absence of 
strikingly clonal features such as the allelic changes highlighted in Figure 4. One way to 
judge the credibility of our calculated likelihood ratios is to create a benchmark reference 
distribution for independent comparisons by conducting analyses on all comparisons 
formed by pairing tumors from different patients, a strategy that has also been used by 
Bollet et al. and others. Our two sets of 22 tumors provide 22X21=462 such independent 
pairings (where each pair contains one 1st primary and one 2nd primary) and the 
likelihood ratios (using (3)) for these pairings are displayed in Figure 5 in the black 
histogram. Superimposed in red with cross-hatching is a histogram of the results from 
the 22 actual within-patient comparisons (from Table 1). The results show that a 
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likelihood ratio of 3.8 to 1 (ln(LR2)=1.3) corresponds to the upper 99th percentile of the 
likelihood ratio distribution for independent tumors, and so values considerably in excess 
of this are unlikely by chance. In this and subsequent analyses we define the region from 
the 95th percentile of the reference distribution to the maximum value recorded as an 
“equivocal” diagnostic region. It can be seen from Figure 5 that for this dataset the 
equivocal region spans ln(LR2) values between -0.9 and 5. Consequently the 13 
patients with likelihood ratios in excess of this region (including case #22) would appear 
to be definitively clonal. For the 4 patients with log LR2 values below -0.9 the evidence 
strongly favors independence. Five patients fall into the “equivocal” zone, with odds 
favoring clonality of 1.9 to 1 (case #2), 9.4 to 1 (case #6), 5.5 to 1 (case #12), 4.1 to 1 
(case #16), and 1 to 1 (case #20). These results give confidence that with good quality 
data the method has the potential to provide definitive classifications for the majority of 
patients.  
 
We have applied the same series of analyses to another published example, this time a 
comparison of LCIS and ILC breast tumors from each of 24 patients (Hwang et al. 2004). 
The purpose of this study was to examine the general hypothesis that LCIS is a 
precursor lesion to invasive breast cancer (ILC), and so the authors were interested in 
the frequency with which clonal relatedness could be identified or proved. The results 
are characterized in the two histograms (Figure 6), calculated in a similar way to Figure 
5 above. That is, all possible pairings of LCIS and ILC tumors from different patients 
were analyzed and the resulting distribution of likelihood ratios is displayed in black. This 
distribution has slightly greater spread than for the Bollet et al. data. In fact, the 
equivocal region stretches from a log LR2 value of 0.3 to a value of 8. The juxtaposition 
of the 24 actual within-patient comparisons in red with the reference histogram again 
produces a group of patients with very strong evidence for clonal relatedness (8 of the 
24 patients). The remaining cases are spread through the “equivocal” (5 patients) and 
“independent” (11 patients) regions.  
 
We performed a similar analysis on our dataset of 21 tumors from 9 patients with 
multiple head and neck cancers, from which our illustrative patient in Figures 1 and 2 
was drawn. Eight of the tumor pairings were considered clinically and pathologically to 
represent tumor recurrences. Only two of these pairings produce strongly clonal 
patterns. These are the two extreme observations on the right of Figure 7 in red. One 
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case, considered clinically to be an independent primary, has odds in favor of clonality of 
78 to 1. However, this falls in the equivocal range of the independent reference 
distribution for this dataset, which spans likelihood ratios that nominally favor the clonal 
hypothesis by large factors, with ln(LR2) values ranging from 4 to 12. 
 
It is noticeable from Figure 7 that the reference distribution of likelihood ratios from 
independent pairings is much broader than for the other two datasets in Figures 5 and 6 
and includes likelihood ratios whose nominal values strongly favor the clonal hypothesis. 
This appears to reflect the fact that the datasets differ with respect to the clarity with 
which allelic changes are detected. Defining the signal strength to be the 90th percentile 
of the absolute values of the detected segment means divided by the standard deviation 
of the residuals, reflecting how separated the larger segment means are from the rest of 
the array values, we find that the mean signal strengths are 4.2 for the Bollet et al. data, 
3.6 for the Hwang et al. data, and 2.4 for the head and neck dataset. High signal 
strength would appear to translate into a tighter reference distribution, and to clearer 
separation of tumor pairs into clusters representing independent pairs and clonal pairs. 
Signal strength also appears to affect the normative values of the likelihood ratios, which 
should generally be less than 1 for independent tumors. The upper 95th percentile of the 
reference distribution for independent pairings is 0.4 to 1 for the Bollet et al. data, 1.3 to 
1 for the Hwang et al. data, but it is 59 to 1 for the head and neck cancer dataset. While 
the arrays were performed on fresh frozen tissue in the studiy by Bollet et al.,, the head 
and neck study used formalin fixed paraffin embedded tissue, and it is well known that 
this source of tissue produces ACGH arrays of much poorer quality. 
 
Finally, we have evaluated the sensitivity of our analyses to the arbitrary choice of 
5.0=c as our parameter representing the relative frequency of clonal mutations in tumor 
pairs that are genuinely clonal. We repeated all of our analyses with 2.0=c and with 
.8.0=c  For the Bollet et al. dataset all three analyses produce consistent diagnoses for 
18 of the 22 patients (82%). [Here we define consistency to represent likelihood ratios 
that are consistently greater than 1 or consistently less than 1.] For all but one of the 
inconsistent cases the likelihood ratio was in the equivocal range for the analyses with 
5.0=c shown in Figure 5. For the Hwang et al. data 19 of the 24 patients (79%) were 
diagnosed consistently. Three of the 5 inconsistent cases were in the equivocal range 
for c=0.5. For the head and neck cancer dataset only 2 of the 15 comparisons had 
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strong evidence for clonality at 5.0=c , and this pattern re-emerged for analyses at 
2.0=c  and 8.0=c . These results suggest that when the analysis provides very strong 
evidence for either CH  or IH  we can be confident of the diagnosis despite the arbitrary 
choice of .c  Conversely, log likelihood ratios in the equivocal range must be viewed with 
caution. The results also support the use of a “signal strength” measure of the clarity of 
the allelic changes observed, as suggested in the previous paragraph, to characterize 
the quality of the array data and the consequent conclusiveness of the resulting 
diagnoses. 
 
  
6. Discussion 
 
Cancer pathology is in a period of fast evolution at present, stimulated by the knowledge 
gained from the sequencing of the human genome, and from related developments 
(Triche 2006). Historically, pathologists have diagnosed cancer on the basis of histologic 
and cytologic features observed by macro- and micro-scopic examination, in recent 
years complemented by various laboratory tests. They make differential diagnoses of 
metastases from second independent primaries on the basis of the comparability of 
these pathologic features, along with relevant clinical information and common sense 
rules regarding this information, such as the expectation that a metastasis would be 
unlikely to have cells that have better differentiation, or an in situ component. However, 
ultimately, it is generally accepted that the crucial features of a cancer that determine its 
behavior and ancestry are the somatic mutations that have accumulated in the tumor 
cells. Thus, examination of these mutational patterns holds the definitive key to the 
accurate differential diagnosis of a metastasis versus a second independent primary 
cancer.  
 
Our goal in this work has been to develop a formal statistical procedure to make the 
differential diagnosis of metastases from second independent primaries on the basis of 
somatic genetic fingerprints obtained from ACGH data. However, this is difficult for many 
reasons. In this article we have focussed on the statistical challenges. The first, and 
possibly the most difficult step, is to organize the voluminous data into a conceptual 
framework that facilitates formal statistical analysis. Because of the richness and 
complexity of the data, this process is necessarily somewhat ad hoc, following a growing 
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tradition in statistical genomics (Speed 2008). After considering numerous options for 
summarizing the data, our belief is that the pivotal information for establishing the clonal 
origin of pairs of tumors lies in the precise comparison of the locations of specific allelic 
gains and losses that are potentially clonal events. Our strategy thus inevitably involves 
multiple stages. We must use segmentation methods to first identify the allelic gains and 
losses, and then we must use the new methods presented in this article to assess the 
closeness of their estimated locations. These comparisons are building blocks of 
information that are then combined with the gross correlation patterns of the losses and 
gains across the genome to determine an overall diagnosis for the patient. In our limited 
efforts to date to validate this strategy we observe that the method has good statistical 
properties in an ideal setting in which there is at most a single allelic loss or gain in each 
chromosome arm, and where the random errors in the marker values in the arrays are 
normally distributed. The data analyses of our various examples using this methodology 
suggest that the method can provide conclusive diagnoses for individual patients where 
the DNA is of high quality and the clonality signals are strong. 
 
A difficult feature of the problem is the fact that the two hypotheses that we are trying to 
distinguish are structured very differently. Under the independence hypothesis, IH , the 
somatic mutational patterns are presumed to have arisen independently. However, we 
know that different genetic loci experience mutations with very different frequencies in 
cancers, and so the method requires knowledge of these “marginal” mutation 
probabilities to effectively filter out the induced correlation that will necessarily occur in 
the mutational profiles of biologically independent tumors. Our knowledge at present of 
these marginal probabilities, which are different for different cancer types, is limited, and 
we chose to estimate them from the relatively small data sets at our disposal. Under the 
clonal hypothesis, CH , the tumors are linked by allelic gains or losses that occurred in 
the original “clonal” cell that led to the cancers, and are thus identical.  Therefore CH  is 
characterized by tumors that share some (at least one) clonal mutations, but these 
tumors may, and usually do, harbor numerous other non-clonal mutations. 
Consequently, we need a method that appropriately weighs the negative evidence of the 
presence of clearly non-clonal mutations against the positive evidence of closely 
matching mutations. We have approached the problem by constructing a likelihood in 
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which the relative frequency of clonal mutations in tumors that are clonal is assumed 
known ( c ), but in practice we have very limited knowledge of this parameter.  
 
Because of the preceding features, we have leaned heavily in interpreting our analyses 
on the use of a “null” distribution of our likelihood ratio statistic, created by comparing 
tumors from different patients, tumors which are necessarily independent. Thus, despite 
the fact that the purpose of our analysis is differential classification of patients into CH  
and IH  our analysis ultimately has a significance testing flavor in which we rely on the 
null distribution of the statistic under IH  to help define the appropriate diagnostic 
classifications. We note that a simple strategy for analyzing the data would be to 
formulate the problem as a significance test, with the diagnosis of independence as the 
null hypothesis, denoted .IH  The broad correlation of gains and losses could then be 
viewed as a set of independent, non-identically distributed multinomials with one 
outcome for each multinomial. Dale (1986) has proposed tests for independent non-
identically distributed multinomials with sparse data, and has studied their properties. In 
our notation her test statistic would be ∑∑∑ −
i j
jkijki
k
jki qqr /)(
2 for nlgj ,,=  and 
nlgk ,,= , where i  represents the chromosome arm, and where .kijiijk ppq =  However, 
we examined this test in our context where each outcome ...r takes the value 1 or 0. We 
found that it does not appear to have good small sample properties, and so we did not 
pursue this approach further. Formulation of the problem as a significance test of IH  
would have followed the strategy we have used previously for the comparison of the 
mutational profiles at candidate markers (Begg et al. 2007, Ostrovnaya et al. 2008). 
 
Application of the method to our various examples demonstrates clearly that it has the 
potential to convincingly establish the clinico-pathological diagnosis, and to change it in 
some patients. However, there are many limitations, and much additional research is 
needed to refine it and to better understand its statistical properties. The key areas for 
further investigation are as follows. First, since we seek a “better” diagnosis than the 
current standard, there is no gold standard benchmark against which to evaluate the 
classifications of the new method. Ultimately, clinical follow-up studies of patients may 
help to determine the gold standard, in that the clinical courses of patients with 
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metastases will generally be much worse than those of patients with new primaries. The 
absence of a gold standard diagnosis also inhibits our ability to calibrate the magnitudes 
of the likelihood ratios produced by the method. Second, the method requires that an 
initial segmentation analysis be performed to identify the allelic gains and losses. This is 
a statistical analysis in and of itself and it is influenced strongly by both the segmentation 
method used and by the parameters of this analysis, namely the significance level for 
detecting an allelic change, and the MAD criterion for ensuring that the signal detected is 
sufficiently strong. Third, our method requires specification of marginal mutation rates in 
each chromosome arm, and a specification of the parameter c  that characterizes the 
strength of the clonality signal. Although we need further research to understand the 
sensitivity of the method to errors in the specification of these parameters, our sensitivity 
analyses provide us with some confidence that diagnoses with high likelihood ratios are 
insensitive to the choice of c . Fourth, we have restricted the entire testing strategy to the 
assumption that each chromosome arm possesses at most one allelic gain or loss. In 
practice, sometimes multiple changes may be observed within a single chromosome 
arm. If these more complex patterns match closely on the two tumors the evidence 
favoring clonality can be greatly enhanced. Indeed we see such a pattern in Figure 8. 
This is from chromosome 5q on patient #13 in the Bollet et al. data, a patient with strong 
overall evidence for clonality. The segmentation for this plot is not restricted to the first 
detected allelic change, as in our previous analyses.  We restricted our method to one-
step changes for analytical simplicity, but the method could benefit from further 
refinement to accommodate complex changes of this nature which would seem to 
provide very strong evidence for clonal relatedness. Finally, we have focussed on the 
statistical issues, but in practice there are numerous practical aspects of molecular 
testing that can greatly influence the data and the resulting analyses. To accomplish 
ACGH testing tumor cells must be isolated for analysis. The tumor cells may be 
substantially contaminated with normal stromal or interstitial cells, and this can radically 
reduce the detectable signal in the allelic changes. As we have seen in our examples, 
the “quality” of the array data can also be affected by whether the tumor samples are 
fresh frozen or obtained from formalin fixed paraffin-embedded archival material.  
 
The “quality” of the array data is reflected in the clarity of the signals that identify allelic 
changes. In poor quality data it is both harder to detect the changes, and also the 
endpoints of the changes are estimated with much greater variability. Our analytic 
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strategy depends on several “tuning” parameters, including the significance level of the 
segmentation algorithm, the MAD criterion used to try to eliminate artifactual signals, and 
the choice of c  to reflect the clonality signal. It also depends on further arbitrary choices, 
such as how to classify changes as gains versus losses, as indicated in our discussion 
of Figure 4, and on the extent to which we elected to reduce the total number of markers 
by averaging adjacent markers. We need further research to determine how to select 
these parameters to optimize the method, recognizing that the choices may be 
dependent at the outset on the overall degree of noise in the data. We view this entire 
methodology as a suggested framework for the task of differential diagnosis of 
metastases and second primaries, and recognize that much additional research is 
needed to refine the methodological details. 
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Table 1 
Clinical Data and Results for Diagnoses of Ipsilateral Breast Cancer (Bollet et al. 2008) 
 
Pt # 
Histology1 
   1st                                   2nd 
Time 
Interval2 Quadrant3 
Clinical 
Diagnosis 
ACGH Results 
LR1              LR2 Diagnosis4 
1 Ductal Ductal 6.5 Same I 4.3 x 10-4 5.0 x 10-4 I 
2 Ductal Lobular 5.3 Same I 1.9 1.9 E 
3 Ductal Ductal 3.1 Same C 1.1 x 104 2.0 x 105 C 
4 Lobular Lobular 3.5 Same C 7.1 x 101 6.6 x 104 C 
5 Ductal Ductal 2.0 Same C 1.1 x 106 3.3 x 1026 C 
6 Lobular Lobular 3.1 Same C 9.4 9.4 E 
10 Lobular Ductal 5.0 Different I 2.6 x 10-2 2.6 x 10-2 I 
11 Lobular Ductal 6.3 Same I 1.5 x 10-4 1.5 x 10-4 I 
12 Lobular Lobular 2.9 Different I 5.5 5.5 E 
13 Ductal Ductal 4.6 Same C 1.4 x 103 1.9 x 1016 C 
14 Lobular Lobular 2.5 Same C 3.7 x 103 1.2 x 108 C 
15 Ductal Ductal 3.3 Same C 3.9 x 102 2.7 x 106 C 
16 Ductal Ductal 3.8 Same I 2.5 x 101 4.1 E 
18 Ductal Ductal 2.2 Same I 8.7 x 10-3 6.3 x 10-4 I 
19 Ductal Ductal 3.0 Same C 2.8 x 10-1 1.8 x 107 C 
20 Ductal Ductal 1.4 Different I 2.2 9.9 x 10-1 E 
21 Ductal Ductal 4.2 Same C 4.8 x 103 1.3 x 1027 C 
22 Ductal Micro-Pap 3.5 Same I 1.3 3.6 x 103 C 
23 Ductal Ductal 0.8 Same C 3.6 x 102 5.5 x 1013 C 
24 Ductal Ductal 1.0 Same C 5.7 x 103 1.8 x 109 C 
25 Ductal Ductal 2.2 Same C 3.5 x 105 2.3 x 1016 C 
26 Ductal Ductal 1.8 Same C 1.8 x 104 7.5 x 1013 C 
 
1. It is presumed generally that tumors must have the same histology to be clonally 
related. 
2. Time interval between tumor diagnoses in years: the longer the interval, the less 
likely it is that the second tumor is a metastasis. 
3. A closer anatomical relationship (same quadrant) is believed to increase the 
probability of clonal relatedness. 
4. I – Independent Primary; C – Clonal (metastasis); E – Equivocal (diagnosis 
uncertain). 
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Figure 1. Whole genome segmentation of tumors from the patient with cancer of the 
mouth described in Sections 2 and 5. The red (blue) lines represent allelic gains (losses) 
as determined by the segmentation algorithm. 
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Figure 2. Detailed view of chromosome 10q segmentation of the patient with cancer of 
the mouth described in Sections 2 and 5. 
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Figure 3. Whole genome segmentation of tumors from the patient with two melanomas 
described in Sections 2 and 5. The red (blue) lines represent allelic gains (losses) as 
determined by the segmentation algorithm. 
. 
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Figure 4. Clonal Mutations from Patient #22 from Bollet et al. (2008)
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Figure 5. Likelihood ratios for patients in Bollet et al. data (blue) superimposed on 
reference histogram from independent tumor pairings from different patients (black). 
Hosted by The Berkeley Electronic Press
 41
 
 
 
Figure 6. Likelihood ratios for patients in Hwang et al. data (blue) superimposed on 
reference histogram from independent tumor pairings from different patients (black). 
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Figure 7. Likelihood ratios for patients in head and neck cancer dataset (blue) 
superimposed on reference histogram from independent tumor pairings from different 
patients (black). 
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Figure 8. Example of a closely matching complex change, from 5q on patient #13 in 
Bollet et al. (2008). 
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